Personally, think the $OCC announcement was solid but it was only tested in 12 patients. It will continue to move because $60M MC is undervalued IMO for what they are sitting on.
$BOT has a Ph2 announcement with a significantly larger cohort. Results will ultimately underpin a lot of their other products in development. If it's good, I can assume it will move more than $OCC.
However, in both cases, there will be selling on news and seeing funds took up a $40M placement in $BOT you may see a churn that will inevitably inhibit its SP growth. But time will tell....
You're right to some degree, but I don't think it will trade like $OCC (assuming it's positive Ph2 results).
Bot Chart, page-2390
-
- There are more pages in this discussion • 11,150 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |